Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Hormones of the Adrenal Glands01:31

Hormones of the Adrenal Glands

Adrenal hormones play a pivotal role in maintaining the body's electrolyte balance and orchestrating responses to stress, showcasing the intricate functions of the adrenal cortex and medulla.
The adrenal cortex, a powerhouse of hormone synthesis, generates over two dozen corticosteroid hormones. The zona glomerulosa produces mineralocorticoids, exemplified by aldosterone, influencing the electrolyte composition of body fluids. The synthesis of glucocorticoids such as cortisol and corticosterone...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of high intensity physical activity compared to routine counseling on renal function decline in patients with type 2 diabetes at high risk for kidney disease - the ACTIDIANE randomized controlled trial.

Diabetes & metabolism·2026
Same author

Energetic adaptations in response to moderate calorie restriction-induced weight loss in normal-weight adults.

Physiology & behavior·2026
Same author

Energy metabolism in resting and postprandial states might not be influenced by menopausal stage in women.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2026
Same author

Prevention of frailty in the elderly: an expert-based evaluation of measures proposed by artificial intelligence.

Geriatric nursing (New York, N.Y.)·2026
Same author

Interest of carbohydrate consumption during endurance exercise: a systematic review of systematic and meta-analyses of RCTs.

The Journal of sports medicine and physical fitness·2026
Same author

Lack of effect of short-term interval training on kidney function in obese adolescent females.

Clinics (Sao Paulo, Brazil)·2026
Same journal

Navigating Adrenal Disease: A Comprehensive, Practical Guide for the Clinician.

Endocrinology and metabolism clinics of North America·2026
Same journal

Adrenal Disorders in Pregnancy.

Endocrinology and metabolism clinics of North America·2026
Same journal

Diagnosis and Management of Adrenocortical Carcinoma.

Endocrinology and metabolism clinics of North America·2026
Same journal

Pheochromocytomas and Paragangliomas.

Endocrinology and metabolism clinics of North America·2026
Same journal

Hereditary Conditions Associated with Adrenocortical Carcinoma, Pheochromocytoma, and Other Adrenal Tumors: Genetic Testing and Management Recommendations.

Endocrinology and metabolism clinics of North America·2026
Same journal

Primary Bilateral Macronodular Adrenal Hyperplasia.

Endocrinology and metabolism clinics of North America·2026
See all related articles

Related Experiment Video

Updated: Jun 16, 2026

Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids
08:02

Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids

Published on: April 25, 2016

Glucocorticoids: a doping agent?

Martine Duclos1

  • 1Department of Sport Medicine and Functional Explorations, University-Hospital (CHU), Hôpital G. Montpied, Clermont-Ferrand, France. mduclos@chu-clermontferrand.fr

Endocrinology and Metabolism Clinics of North America
|February 4, 2010
PubMed
Summary
This summary is machine-generated.

Glucocorticoids (GCs) should remain banned in sports. Scientific evidence shows GCs offer performance-enhancing effects in athletes and pose health risks, justifying their inclusion on the World Antidoping Agency

More Related Videos

A Chemical Screening Procedure for Glucocorticoid Signaling with a Zebrafish Larva Luciferase Reporter System
13:22

A Chemical Screening Procedure for Glucocorticoid Signaling with a Zebrafish Larva Luciferase Reporter System

Published on: September 10, 2013

Related Experiment Videos

Last Updated: Jun 16, 2026

Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids
08:02

Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids

Published on: April 25, 2016

A Chemical Screening Procedure for Glucocorticoid Signaling with a Zebrafish Larva Luciferase Reporter System
13:22

A Chemical Screening Procedure for Glucocorticoid Signaling with a Zebrafish Larva Luciferase Reporter System

Published on: September 10, 2013

Area of Science:

  • Sports Medicine
  • Pharmacology
  • Anti-doping Science

Background:

  • International sports federations advocate for removing glucocorticoids (GCs) from banned substance lists.
  • Arguments cite widespread sports medicine use and lack of demonstrated ergogenic activity.

Purpose of the Study:

  • To evaluate the scientific evidence for ergogenic effects of GCs.
  • To assess the health risks associated with GC use in athletes.
  • To determine if GCs should remain classified as doping agents.

Main Methods:

  • Literature review of scientific studies on glucocorticoids.
  • Analysis of evidence for ergogenic effects in animal and human models.
  • Examination of documented health risks of glucocorticoid administration.

Main Results:

  • Scientific evidence demonstrates that GCs mediate ergogenic effects in both animals and humans.
  • The health risks associated with the use of GCs are well-characterized.
  • GCs possess properties that constitute doping.

Conclusions:

  • Glucocorticoids are doping agents due to their ergogenic potential and associated health risks.
  • GCs must remain on the World Antidoping Agency's list of prohibited substances.
  • Continued prohibition of GCs is essential for fair and safe sports competition.